Nanobodies TM targeting amyloid beta as potential therapeutics for Alzheimer's disease

AuthorSearch for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for:
TypeArticle
Subjectamyloid beta; Alzheimer's disease; Nanobodies; passive immunotherapy
AbstractActive and passive immunization strategies targeting amyloid beta are currently being developed as a potential therapy to treat Alzheimer's disease (AD). Both approaches have shown efficacy in animal models, while passive vaccination is expected to be safer in the clinical context. We have explored the use of amyloid beta targeting Nanobodies for passive immunotherapy of AD. Nanobodies are 12-15 kDa protein domains derived from camelid Heavy-Chain antibodies with unique characteristics that offer many advantages over the use of conventional monoclonal antibodies.
LanguageEnglish
AffiliationNRC Institute for Biological Sciences; National Research Council Canada
Peer reviewedYes
NPARC number21275177
Export citationExport as RIS
Report a correctionReport a correction
Record identifier80d443d9-e752-4846-96d9-b7d20f33225c
Record created2015-05-22
Record modified2016-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)